ERBB2 and neoplasm: While many signatures showed significant hazard ratios in univariable analysis (Supplementary Fig. S1) statistical significance in the comparably challenging multivariable analysis (correcting for tumor size, age, and grade) was limited to only a few signatures in the two HER2-negative luminal clinical assessment groups, including SDPP, HDPP and ROR-S in ER+/HER2−/LN− endocrine treated tumors, and Oncotype DX in ER+/HER2−/LN+ endocrine treated tumors (Fig. 4C,D).